

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-8. (Canceled)

9. (Currently Amended) A method for producing the Tr1-like regulatory cells of claim 4, which method comprises energizing CD4<sup>+</sup> CD25<sup>-</sup> T cells by contacting the CD4<sup>+</sup> CD25<sup>-</sup> T cells with an anergic state inducing agent *ex vivo* and *or in vivo*.

10. (Previously Presented) The method of claim 9, wherein  
(i) the anergic state inducing agent comprises CD4<sup>+</sup> CD25<sup>+</sup> T cells; or  
(ii) the anergic state inducing agent is a substance or a mixture of substances mimicking the role of CD4<sup>+</sup> CD25<sup>+</sup> T cells.

11. (Previously Presented) The method of claim 10, wherein the anergic state inducing agent comprises CD4<sup>+</sup> CD25<sup>+</sup> T cells and said method comprises co-culturing the CD4<sup>+</sup> CD25<sup>-</sup> T cells with CD4<sup>+</sup> CD25<sup>+</sup> T cells.

12.-28. (Canceled)

29. (New) The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

30. (New) The method of claim 29, wherein said Tr1-like regulatory cells inhibit the proliferation of syngeneic CD4<sup>+</sup> T cells.